Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the " Company " or " Canntab "), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein , currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022 . Mr. Goldstein replaces the outgoing CEO of the Board Larry Latowsky who... Read More